CD38 and Miyoshi myopathy: Recently, preliminary results from a phase II clinical trial (NCT01084252) have demonstrated superior anti-tumor activity of the combination of dexamethasone and isatuximab compared to this anti-CD38 mAb alone in MM patients with at least three prior lines of therapy.